Nasopharyngeal Cancer - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 319 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides an overview of the Nasopharyngeal Cancer (Oncology) pipeline landscape.

Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasopharyngeal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasopharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 13, 7 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 8, 2 and 5 molecules, respectively.

Nasopharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngeal Cancer - Overview 7
Nasopharyngeal Cancer - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Nasopharyngeal Cancer - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 27
Advenchen Laboratories LLC 27
Ambrx Inc 27
arGEN-X BV 28
Atara Biotherapeutics Inc 28
AVEO Pharmaceuticals Inc 29
BeiGene Ltd 29
BioDiem Ltd 30
Biomics Biotechnologies Co Ltd 30
Bristol-Myers Squibb Company 31
CBT Pharmaceuticals Inc 31
Celgene Corp 32
Cell Medica Ltd 32
F. Hoffmann-La Roche Ltd 33
GlaxoSmithKline Plc 33
Incyte Corp 34
Jiangsu Hengrui Medicine Co Ltd 35
MedImmune LLC 35
Merck & Co Inc 36
Merck KGaA 36
Millennium Pharmaceuticals Inc 37
Neonc Technologies Inc 37
Novartis AG 38
Ono Pharmaceutical Co Ltd 38
Otsuka Holdings Co Ltd 39
Systimmune Inc 39
Tessa Therapeutics Pte Ltd 40
Theravectys SA 40
Viracta Therapeutics Inc 41
Yabao Pharmaceutical Group Co Ltd 41
Nasopharyngeal Cancer - Drug Profiles 42
alisertib - Drug Profile 42
Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 48
apatinib - Drug Profile 49
APG-1387 - Drug Profile 55
ARGX-110 - Drug Profile 56
ATA-129 - Drug Profile 61
atezolizumab - Drug Profile 64
avelumab - Drug Profile 84
azacitidine - Drug Profile 95
baltaleucel-T - Drug Profile 101
bevacizumab - Drug Profile 103
BGBA-317 - Drug Profile 115
CBT-501 - Drug Profile 118
Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile 120
Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer - Drug Profile 121
Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 122
Cellular Immunotherapy for Oncology - Drug Profile 123
Cellular Immunotherapy for Oncology - Drug Profile 124
Cellular Immunotherapy for Oncology - Drug Profile 126
Cellular Immunotherapy for Oncology and Infectious Disease - Drug Profile 127
Cellular Immunotherapy to Target EPCAM for Oncology - Drug Profile 128
Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 129
Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile 130
DC-120 - Drug Profile 131
donafenib - Drug Profile 132
durvalumab + tremelimumab - Drug Profile 134
EBViNT - Drug Profile 140
Epstein-Barr virus vaccine - Drug Profile 141
ficlatuzumab - Drug Profile 142
GSK-2849330 - Drug Profile 146
INCB-62079 - Drug Profile 147
ipilimumab - Drug Profile 148
ipilimumab + nivolumab - Drug Profile 159
JS-001 - Drug Profile 167
MAK-683 - Drug Profile 169
Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 170
Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 171
MVA vaccine - Drug Profile 172
NEO-212 - Drug Profile 173
nimotuzumab - Drug Profile 175
nivolumab - Drug Profile 180
OPB-111077 - Drug Profile 229
PDR-001 - Drug Profile 230
pembrolizumab - Drug Profile 233
SHR-1210 - Drug Profile 294
SIM-005A - Drug Profile 296
Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer - Drug Profile 297
SV-638 - Drug Profile 298
TT-10 - Drug Profile 299
Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 301
Vaccine for Oncology - Drug Profile 302
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 303
Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma - Drug Profile 304
VRx-3996 - Drug Profile 305
Nasopharyngeal Cancer - Dormant Projects 307
Nasopharyngeal Cancer - Discontinued Products 308
Nasopharyngeal Cancer - Product Development Milestones 309
Featured News & Press Releases 309
Appendix 314
Methodology 314
Coverage 314
Secondary Research 314
Primary Research 314
Expert Panel Validation 314
Contact Us 314
Disclaimer 315

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Nasopharyngeal Cancer - Pipeline by Ambrx Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2017
Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by BeiGene Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2017
Nasopharyngeal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Celgene Corp, H2 2017
Nasopharyngeal Cancer - Pipeline by Cell Medica Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Nasopharyngeal Cancer - Pipeline by Incyte Corp, H2 2017
Nasopharyngeal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by MedImmune LLC, H2 2017
Nasopharyngeal Cancer - Pipeline by Merck & Co Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2017
Nasopharyngeal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Neonc Technologies Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2017
Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Systimmune Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2017
Nasopharyngeal Cancer - Pipeline by Viracta Therapeutics Inc, H2 2017
Nasopharyngeal Cancer - Pipeline by Yabao Pharmaceutical Group Co Ltd, H2 2017
Nasopharyngeal Cancer - Dormant Projects, H2 2017
Nasopharyngeal Cancer - Discontinued Products, H2 2017